Since TRIM32 was found to accelerate oxaliplatin resistance and TRIM44 to enhance the doxorubicin resistance of HCC cells in 2016, accumulating evidence has supported the causative drug‐resistance role in TRIM members and suggested targeting TRIM family proteins to augment the sensitivity of HCC toward chemotherapy.12, 36, 42, 45. The gene discussed is TRIM32; the disease is hepatocellular carcinoma.